Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 23186

    +

    P2.01-063 - Outcomes of Patients with Oligometastatic Non-Small Cell Lung Cancer Who Were Treated with Radical Treatment (ID 8816)

    09:00 - 09:00  |  Author(s): F. Selcukbiricik
    • Abstract
    • Slides

    Background:
    Patients with oligometastatic non-small cell lung cancer (NSCLC) represent an indolent phenotype who may benefit from aggressive therapy and experience long-term overall survival (OS). Previous several small retrospective studies have showed that aggressive therapies for both the primary tumor and the metastases might be beneficial for patients with oligometastatic NSCLC compared with patients that did not receive aggressive treatment. The aim of this study was to determine the efficacy of aggressive treatment for patients with oligometastatic NSCLC.
    
    Method:
    We retrospectively analyzed 40 patients with oligometastatic NSCLC who were treated with aggressive treatments. Response rates, progression-free survival (PFS) and OS were evaluated.
    
    Result:
    Median age was 58 years, the majority of patients were male (67.5%), and have adenocarcioma histology (77.5%) and ECOG PS 0-1 (92.5%). Oligometastase locations were brain (55%), adrenal gland (22.5%), bone (15%), lung (5%), and other (2.5%). Oligometastatic disease was mostly limited: 80% of patients had metastases confined to one involved organ, and the majority of patients (57.5 %) presented with a solitary metastasis. Primary tumor treatments were concomitant chemoradiotherapy (60%), surgery (17.5%), chemotherapy (17.5%) and sequential radiotherapy (5%). On the other hand, metastase treatments were consisted of radiosurgery (77.5%), metastasectomy (17.5%) and radiosurgery and metastasectomy (5%). After agressive treatment objective response rate was 82.5%. At the median follow-up of 16.5 months, the median PFS and OS intervals were 15.5 (95% CI 9.3-21.7) and 21.9 (95% CI 13.5-30.2) months, respectively.
    
    Conclusion:
    Radically aggressive treatment for both the primary tumor and the metastases is reasonable and effective therapeutic option to provide long-term survival rates in selected patients with oligometastatic NSCLC. Further studies are needed, preferably prospective and randomized that analyze the efficacy and safety of aggressive ablative treatment for these patients.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.